Guanghai Dai - Concepedia

Author

Guanghai Dai

Chinese PLA General Hospital ORCID

Also Known As

G. Dai, G.-H. Dai, G.H. Dai, Gong-Qiang Dai, Guang-Hai Dai, Guang-hai Dai, Guanghai Dai

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

Chinese PLA General Hospital Chinese People's Liberation Army Henan Cancer Hospital Sun Yat-sen University Cancer Center Sun Yat-sen University

About

Guanghai Dai is an author at Chinese PLA General Hospital specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	59
2	Immunology	3	3	59
3	Pathology	3	3	59
4	Cell Biology	1	1	24
5	Cancer Cell Biology	1	1	24

Guanghai Dai

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial Zixian Wang, Chengxu Cui, Jun Yao, Cancer Cell	2022	523
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432 F. Wang, Xiaoli Wei, Fenggong Wang, Annals of Oncology	2019	466
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02) Feng‐Hua Wang, Xiaoli Wei, Jifeng Feng, Journal of Clinical Oncology	2021	336
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial Shukui Qin, Jin Li, Liwei Wang, Journal of Clinical Oncology	2018	252
Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study Zhi Peng, Tianshu Liu, Jia Wei, Cancer Communications	2021	182
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2) Jianming Xu, Yi Li, Qingxia Fan, Nature Communications	2022	147
Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer Miaomiao Gou, Tongtong Qu, Zhikuan Wang, Journal of Immunology Research	2021	55
Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China Miaomiao Gou, Niansong Qian, Yong Zhang, Frontiers in Oncology	2022	43
<p>Efficacy and safety of nivolumab for metastatic biliary tract cancer</p> Miaomiao Gou, Yong Zhang, Haiyan Si, OncoTargets and Therapy	2019	37
The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer Jun Jia, Pengfei Zhang, Miaomiao Gou, Disease Markers	2019	35

Page 1